Literature DB >> 16353210

Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy.

Pooja R Rohatgi1, Stephen G Swisher, Arlene M Correa, Tsung T Wu, Zhongxing Liao, Ritsuko Komaki, Garrett L Walsh, Ara A Vaporciyan, David C Rice, Robert S Bresalier, Jack A Roth, Jaffer A Ajani.   

Abstract

BACKGROUND: The current study tested the hypothesis that the clinical outcome of patients with localized esophageal carcinoma after preoperative chemoradiotherapy (CTRT) depends on histology.
METHODS: The authors stratified patients by adenocarcinoma (ACA) or squamous cell carcinoma (SCC) and compared the overall survival (OS) and patterns of failure among patients achieving pathologic complete response (pathCR) and <pathCR after preoperative CTRT. A correlation between baseline clinical stage and posttherapy pathologic response was made for ACA and SCC.
RESULTS: Of the 235 patients who underwent preoperative CTRT, 42 (18%) had SCC and 193 (82%) had ACA. In the ACA group, 56 patients (29%) achieved a pathCR and in the SCC group 13 patients (31%) achieved a pathCR. In the ACA group, a larger proportion of pathCR patients (n=44; 79%) than <pathCR patients (n=82; 60%) were alive at the time of last follow-up (P=0.01) and pathCR patients had a longer OS than <pathCR patients (P=0.0006). However, in the SCC group OS or proportion alive did not differ significantly between pathCR and <pathCR patients (P>or=0.05). In the ACA group, a greater portion of <pathCR patients (32%) than pathCR patients (16%) had distant metastases (P=0.02) and the distant metastases-free survival of pathCR patients was longer than that of <pathCR patients (P=0.0012). In the SCC group, the proportion or time to distant-metastases did not differ significantly. Pretreatment clinical stage did not correlate with pathologic response for either histology.
CONCLUSIONS: The results of the current study suggest that the clinical biology of SCC and ACA is different after CTRT. An investigation of molecular and patient genetics is needed to improve therapy. Copyright (c) 2005 American Cancer Society.

Entities:  

Mesh:

Year:  2006        PMID: 16353210     DOI: 10.1002/cncr.21601

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

Review 1.  Neoadjuvant treatment of esophageal cancer.

Authors:  Nicholas P Campbell; Victoria M Villaflor
Journal:  World J Gastroenterol       Date:  2010-08-14       Impact factor: 5.742

2.  Patients with Non-response to Neoadjuvant Chemoradiation for Esophageal Cancer Have No Survival Advantage over Patients Undergoing Primary Esophagectomy.

Authors:  Guillaume S Chevrollier; Danica N Giugliano; Francesco Palazzo; Scott W Keith; Ernest L Rosato; Nathaniel R Evans Iii; Adam C Berger
Journal:  J Gastrointest Surg       Date:  2019-02-26       Impact factor: 3.452

3.  Radiation therapy in the postoperative management of esophageal cancer.

Authors:  Salma K Jabbour; Charles R Thomas
Journal:  J Gastrointest Oncol       Date:  2010-12

4.  Signet Ring Cell Features are Associated with Poor Response to Neoadjuvant Treatment and Dismal Survival in Patients with High-Grade Esophageal Adenocarcinoma.

Authors:  Daniel Solomon; Muhammad Abbas; Yael Feferman; Riad Haddad; Gali Perl; Yulia Kundel; Sara Morgenstern; Nikolai Menasherov; Hanoch Kashtan
Journal:  Ann Surg Oncol       Date:  2021-03-11       Impact factor: 5.344

5.  Non responders to neoadjuvant chemoradiation for esophageal cancer: why better prediction is necessary.

Authors:  Chantal M den Bakker; Justin K Smit; Anna M E Bruynzeel; Nicole C T van Grieken; Freek Daams; Sarah Derks; Miguel A Cuesta; John T M Plukker; Donald L van der Peet
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

6.  Role of interleukin 1 beta in esophageal squamous cell carcinoma.

Authors:  Miao-Fen Chen; Ming-Shian Lu; Ping-Tsung Chen; Wen-Cheng Chen; Paul-Yang Lin; Kuan-Der Lee
Journal:  J Mol Med (Berl)       Date:  2011-09-13       Impact factor: 4.599

7.  p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis.

Authors:  David W Cescon; Penelope A Bradbury; Kofi Asomaning; Jessica Hopkins; Rihong Zhai; Wei Zhou; Zhaoxi Wang; Matthew Kulke; Li Su; Clement Ma; Wei Xu; Ariela L Marshall; Rebecca Suk Heist; John C Wain; Thomas J Lynch; David C Christiani; Geoffrey Liu
Journal:  Clin Cancer Res       Date:  2009-04-21       Impact factor: 12.531

8.  Pathologic Complete Response Is an Independent Predictor of Improved Survival Following Neoadjuvant Chemoradiation for Esophageal Adenocarcinoma.

Authors:  Raed M Alnaji; William Du; Emmanuel Gabriel; Smit Singla; Kristopher Attwood; Hector Nava; Usha Malhotra; Steven N Hochwald; Moshim Kukar
Journal:  J Gastrointest Surg       Date:  2016-06-03       Impact factor: 3.452

Review 9.  Surgical indications and optimization of patients for resectable esophageal malignancies.

Authors:  Joshua C Grimm; Vicente Valero; Daniela Molena
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

10.  Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival.

Authors:  James M Donahue; Francis C Nichols; Zhuo Li; David A Schomas; Mark S Allen; Stephen D Cassivi; Aminah Jatoi; Robert C Miller; Dennis A Wigle; K Robert Shen; Claude Deschamps
Journal:  Ann Thorac Surg       Date:  2009-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.